Nocturia: the most common cause of a poor night’s sleep, say experts on World Sleep Day
On World Sleep Day, scientists are highlighting the number one reason that people are waking up at night – nocturia (otherwise known as the need to get up and urinate more than once during the night).1,2 It often has one or more contributing factors such as an overproduction of urine, reduced bladder capacity; certain illnesses and medications are also potential contributors.2,6 Although it is most common in older adults, nocturia can affect people of all ages and frequent sleep disturbances significantly impact daily living and can be a sign of more serious health conditions.2,3,4,5
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180315005990/en/
“Nocturia’s disruption to deep sleep results in reduced productivity and alertness that can affect multiple areas of an individual’s life during the day,” said Jens-Peter Nørgaard, Medical Director of Ferring Pharmaceuticals and Professor of Urology at Ghent University, Belgium. “From making it difficult to manage a busy daily schedule to negatively impacting productivity at work, sleep disruption has significant impact far beyond fatigue or night-time inconvenience.”
The effect that sleep disruption can have was measured recently in a study by Nokia Health, which designs smart health devices and apps. In the study sleep patterns were measured using Nokia sleep sensors and compared to self-reported quality of sleep. Of the over 19,000 people surveyed it was shown that frequency of nightly awakenings was the most important factor in getting a good night’s sleep – more than the total duration of sleep or the time people went to bed.7
Lack of sleep from nocturia can lead to impaired daytime functioning, as well as reduced productivity and alertness.3,4,5 These frequent sleep interruptions are important as uninterrupted sleep is needed to sustain physical (including the immune system), mental and emotional health.8
“People often ignore sleep disturbance from nocturia, but this can produce significant disruption to daytime functioning,” said Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Science at University of California, San Francisco. “It is important this is discussed with a healthcare professional, as this disruption is not just harmful in itself but can also be an indicator of more serious health conditions.”
Nocturia can also be a symptom of more serious health problems such as high blood pressure, diabetes and heart disease.2 The impact of sleep disturbances can also lead to greater risk of serious health conditions such as increased risk of diabetes, weakened immune systems and heart disease.9 Similarly, individuals who suffer from chronic sleep disturbances experience reduced cognitive functioning, which can impact productivity, relationships and careers.8
About World Sleep Day
World Sleep Day is an annual event intended to be a celebration of sleep and a call to action on important issues related to sleep. It is organised by the World Sleep Day Committee of the World Sleep Society (founded by World Association of Sleep Medicine and the World Sleep Federation) and will take place on Friday 16th March 2018.10
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Ferring is a proud supporter of World Sleep Day
1 Benefield LE. Facilitating Aging in Place: Safe, Sound, and Secure, An Issue of Nursing Clinics. 2014
2 National Association for Continence. Nocturia web page. Last accessed 2017.
3 Bliwise DL et al. J Clin Sleep Med 2015;11:53–5.
4 Bliwise DL et al. Eur Urol Suppl 2014;13:e591–e591a.
5 Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int. 2003;91(3):190–5
6 Park, H.K and Kim, H.G., Current Evaluation and Treatment of Nocturia, Korean J Urol. Aug 2013; 54(8): 492–498. page 492
7 Roitmann, E., O. Bellahsen, and A. Chieh. "Perceived sleep quality of sleep profiles derived from connected sleep detector data." Sleep Medicine 40 (2017): e281-e282.
8 Laureanno, P. Ellsworth, P., Demystifying Nocturia: Identifying the Cause and Tailoring the Treatment. Urol Nurs. 2010;30(5):276-287.
9 Orzel-Gryglewska, J. Consequences of Sleep Deprivation. International Journal of Occupational Medicine and Environmental Health 2010; 23(1): 95-114. doi:10.2478/v10001-010-0004-9.
10 World Sleep Day website. Homepage. [Last accessed February 2017] Available at: www.worldsleepday.org
Senior Manager, Corporate Communications
+41 58 451 40 23 (direct)
+41 79 191 0486 (mobile)
Head of Corporate Communications
+41 58 301 09 52 (direct)
+41 79 191 06 32 (mobile)
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
NY-YOOZOO-GAMES26.3.2019 00:02:12 CET | Pressemeddelelse
Game of Thrones Winter is Coming™ Launches Worldwide
MD-EARTH-NETWORKS26.3.2019 00:02:12 CET | Pressemeddelelse
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA
MA-BLUEBIRD-BIO25.3.2019 23:42:10 CET | Pressemeddelelse
bluebird bio Statement on European Regulatory Status of LentiGlobin™
NJ-CELGENE25.3.2019 21:32:03 CET | Pressemeddelelse
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
UK-THALASSAEMIA-SOCIETY25.3.2019 20:52:11 CET | Pressemeddelelse
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia
INSTITUT-CURIE25.3.2019 17:56:11 CET | Pressemeddelelse
Historic Partnership between the Weizmann Institute of Science and Institut Curie
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum